# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cathie Wood's flagship ARK Innovation ETF has been navigating through significant losses, showcasing the challenges faced b...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Verve Therapeutics (NASDAQ:VERV) with a Buy and maintains $15 pri...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
On Thursday, Cathie Wood-led Ark Invest made a significant move by selling shares of Coinbase Global Inc (NASDAQ:COIN), despite...
Stifel analyst Dae Gon Ha maintains Verve Therapeutics (NASDAQ:VERV) with a Buy and lowers the price target from $56 to $40.
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dipping over 1% on Tuesday. The Dow traded down ...